- Khiron has received all necessary licenses and authorizations
allowing full spectrum, high-CBD medical cannabis products to be
exported from Colombia for import
and commercialization in Peru
- Full spectrum high CBD medical cannabis will be supplied by
Khiron Colombia and manufactured and distributed to patients under
the previously announced agreement with Farmacia Universal
- First patient prescriptions anticipated to be filled in Q3
2020
- Receipt of import license and corresponding Colombian
authorizations complete all requirements for entry into the
Peruvian high CBD medical cannabis market
- Entry to Peru comes as Company
surpasses 1,000 medical cannabis patient prescriptions milestone in
Colombia
TORONTO, July 23, 2020 /CNW/ - Khiron Life Sciences
Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF),
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America and Europe, announced today that it has
received import licenses and all necessary authorizations from the
Directorate General of Drug Supplies and Drugs (DIGEMID)
for the import and commercialization of full spectrum, high-CBD
medical cannabis products from Khiron Colombia into
Peru.
"Successfully completing all licensing, import and distribution
requirements allows us to bring our full spectrum, high CBD medical
cannabis products into Peru. We
have an experienced country management team in place in
Lima and, together with our
distribution partner Farmacia Universal, are now positioned to give
patients in Peru greater access to
medical cannabis therapies. Additionally, we anticipate fulfilling
all necessary requirements to commercialize high-THC medical
cannabis products in Peru during
Q4 2020," comments Luis Marquez,
Khiron Peru Country Manager.
In Peru, only registered pharmaceutical establishments that
have received Good Storage Practices (GSP) certification are
authorized to participate in the wholesale import and
commercialization of cannabis products. Khiron Peru is a GSP
certified, registered pharmaceutical establishment, and Farmacia
Universal has all required permits, including Good Manufacturing
Practices (GMP) certification, to distribute medical cannabis final
products to patients through pharmacies under the previously
announced agreement with Khiron.
With receipt of the final licenses and authorizations from
DIGEMID, Khiron Peru is now fully authorized to import full
spectrum, high-CBD medical cannabis from Khiron Colombia, which is
now fully authorized by the Narcotics National Fund (NNF) in
Colombia for the export to
Peru. The Company anticipates
prescriptions can be filled commencing in Q3 2020.
"Entry to the Peru medical
cannabis market continues our relentless focus on meeting patient
needs in Latin America and
globally. We are currently the only company in Colombia that has dispensed medical cannabis
to patients and have now surpassed our first 1,000 medical cannabis
patient prescriptions milestone. This, despite a global pandemic
that has slowed down many of the world's economies, represents a
very important achievement for us," comments Alvaro Torres, Khiron CEO and director.
About Khiron Life Sciences Corp.
Khiron is a vertically integrated medical and CPG cannabis
company with core operations in Latin
America, and operational activity in Europe and North America. Khiron is the
leading cannabis company in Colombia and the first company licensed in
Colombia for the cultivation,
production, domestic distribution, and international export of both
low and high THC medical cannabis products. The Company has
presence in Mexico, Peru, Uruguay, Brazil, UK, Spain and Germany, where it is positioned to begin sales
of medical cannabis.
Leveraging its first-mover advantage, and patient oriented
approach, Khiron combines global scientific expertise, product
innovation, agricultural infrastructure, wholly-owned medical
clinics, and online doctor education programs to drive prescription
and brand loyalty to address priority medical conditions. Its
Wellbeing unit launched the first branded CBD skincare brand in
Colombia, with KuidaTM
now marketed in multiple jurisdictions in Latin America, the US and UK. The Company is
led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and
diverse executive team and Board of Directors.
Visit Khiron online at www.khiron.ca,
investors.khiron.ca and on Instagram @khironlife.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-to-commercialize-medical-cannabis-in-peru-301098544.html
SOURCE Khiron Life Sciences Corp.